Bone Therapeutics was granted an additional €2MM (~US $2.15MM) in non-dilutive funding from the Belgian Walloon Region government, bringing the total non-dilutive funding received within 2015 to €5MM.
The new funding will support a 2-year study of ALLOB® allogeneic bone cell therapy, investigating the impact of proteins on bone reconstruction. This data will feed ongoing proof-of-concept studies in the treatment of delayed-union fractures and in spinal fusion.
Bone Therapeutics was granted an additional €2MM (~US $2.15MM) in non-dilutive funding from the Belgian Walloon Region government, bringing the total non-dilutive funding received within 2015 to €5MM.
The new funding will support a 2-year study of ALLOB® allogeneic bone cell therapy, investigating the impact of proteins on...
Bone Therapeutics was granted an additional €2MM (~US $2.15MM) in non-dilutive funding from the Belgian Walloon Region government, bringing the total non-dilutive funding received within 2015 to €5MM.
The new funding will support a 2-year study of ALLOB® allogeneic bone cell therapy, investigating the impact of proteins on bone reconstruction. This data will feed ongoing proof-of-concept studies in the treatment of delayed-union fractures and in spinal fusion.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
